Your Search Results

What bench testing teaches us about real world PCI

19 May 2026 – From EuroPCR 2026

This session explores bench testing insights into real-world percutaneous coronary interventions (PCI). Topics include comparative expansion ratios of coronary stents, prognostic assessments after drug-coated balloon treatments, mechanical performance of magnesium scaffolds in bifurcations, preclinical safety and computational modeling of bioresorbable polymer-coated stents, and evaluations of commonly...

When the anterior leaflet gets in the way: mitral leaflet modification before TMVR

19 May 2026 – From EuroPCR 2026

This session addresses the intricacies of mitral leaflet modification techniques prior to transcatheter mitral valve replacement (TMVR). It features innovative approaches such as LAMPOON-assisted valve-in-ring replacement, balloon-assisted leaflet translocation, and strategies to overcome the challenges posed by mitral annular calcification.

Complication management in CTO PCI - Part 1

19 May 2026 – From EuroPCR 2026

This session addresses complication management during chronic total occlusion (CTO) percutaneous coronary interventions. It covers strategies for unexpected coronary complications, managing tamponade without visible perforation, rescue techniques for atherectomy-related perforations, managing dry pericardial tamponade after septal branch perforation, and challenges when retrograde approaches encounter thrombosis in...

How to face resistent hypertension: when pharmacological treatment is not an option

19 May 2026 – From EuroPCR 2026

Focused on resistant hypertension, this session explores interventional options when pharmacological treatments fall short. It discusses urgent intervention indications, complex cases involving renal artery occlusion, and the role of fractional flow reserve (FFR) in managing pan-vascular disease associated with hypertension.

The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

18 Sep 2022

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

Author

Jonathan Curio

The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

Outcomes in patients with atrial fibrillation randomized to receive LAA closure or oral anticoagulation: Primary results of the CHAMPION-AF clinical trial

28 Mar 2026

During the first Late-Breaking Trial session of the 2026 ACC Congress held in New Orleans, Saibal Kar, principal investigator of the CHAMPION-AF trial, presented the 3-year results of this groundbreaking study, which were simultaneously published in the NEJM (DOI: 10.1056/NEJMoa2517213).